QUICK READ: STAT News post entitled “Early peek at data on Gilead drug suggests patients are responding to treatment” was irresponsible and had led to investors gambling on a drug that has no substantial clinical data behind it. Both Gilead and the hospital urged caution. “Information from an internal forum for research colleagues concerning work in progress was released without authorization,” said University of Chicago Medicine. “Drawing any conclusions at this point is premature and scientifically unsound.”

Investors react to irresponsible news

SUMMARY: According to a new report from the Institute for Clinical and Economic Review released on Tuesday, combined price hikes from seven drugs, in 2017 and 2018, contributed to a $5.1 billion increase in U.S. spending. None of those drugs had new important evidence to support the price increase, the study concluded. Why is this happening?

SUMMARY: Via Business Insider “CEOs have for decades chanted the mantra of shareholder supremacy and placed cost-cutting and short-term profits above all else. That mindset, however, just might be changing.” It might be changing in other industries but within pharma, the mindset is still “short term balance sheet”.